Clinical Trial Update: High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update reports results for high-dose busulfan combined with bortezomib in high-risk multiple myeloma patients undergoing stem cell t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BUSULFAN (Busulfan)
• Bortezomib (bortezomib)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2013-12-16